Integra LifeSciences Declines on FY Outlook Cut After Supply Chain Issues

Dow Jones

2025/10/31

By Kelly Cloonan

Shares of Integra LifeSciences slid as the company cut its full-year outlook after supply chain interruptions dragged on revenue growth in its latest quarter.

The stock dropped 25% to $11.62 on Thursday. Shares are down 49% this year.

The medical technology company now forecasts adjusted earnings per share of $2.19 to $2.24 for the year, lowering the upper range of its prior projection of $2.19 to $2.29.

Integra also cut its revenue outlook, guiding for sales of $1.62 billion to $1.64 billion, compared to $1.66 billion to $1.68 billion previously.

The updated guidance comes after Integra said third-quarter revenue was negatively affected by two supply interruptions. Chief Executive Mojdeh Poul said the company is working to strengthen its supply chain and quality management system, and is confident it can improve overall performance.

For the third quarter, Integra narrowed its loss to $5.4 million, or 7 cents a share, from a loss of $10.7 million, or 14 cents a share, a year earlier.

Adjusted earnings per share were 54 cents, ahead of estimates of 43 cents a share according to analysts polled by FactSet.

Revenue rose 5.6% to $402.1 million, missing analyst expectations of $414.2 million.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

October 30, 2025 12:14 ET (16:14 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2579124024"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579124024\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579124024?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 00:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579124024","market":"us","top_or_hot":-1,"title":"Integra LifeSciences Declines on FY Outlook Cut After Supply Chain Issues","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Integra LifeSciences slid as the company cut its full-year outlook after supply chain interruptions dragged on revenue growth in its latest quarter. \n</p>\n<p>\n  The stock dropped 25% to $11.62 on Thursday. Shares are down 49% this year. \n</p>\n<p>\n  The medical technology company now forecasts adjusted earnings per share of $2.19 to $2.24 for the year, lowering the upper range of its prior projection of $2.19 to $2.29. \n</p>\n<p>\n  Integra also cut its revenue outlook, guiding for sales of $1.62 billion to $1.64 billion, compared to $1.66 billion to $1.68 billion previously. \n</p>\n<p>\n  The updated guidance comes after Integra said third-quarter revenue was negatively affected by two supply interruptions. Chief Executive Mojdeh Poul said the company is working to strengthen its supply chain and quality management system, and is confident it can improve overall performance. \n</p>\n<p>\n  For the third quarter, Integra narrowed its loss to $5.4 million, or 7 cents a share, from a loss of $10.7 million, or 14 cents a share, a year earlier. \n</p>\n<p>\n  Adjusted earnings per share were 54 cents, ahead of estimates of 43 cents a share according to analysts polled by FactSet. \n</p>\n<p>\n  Revenue rose 5.6% to $402.1 million, missing analyst expectations of $414.2 million. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 30, 2025 12:14 ET (16:14 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Integra LifeSciences Declines on FY Outlook Cut After Supply Chain Issues</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntegra LifeSciences Declines on FY Outlook Cut After Supply Chain Issues\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-31 00:14</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Integra LifeSciences slid as the company cut its full-year outlook after supply chain interruptions dragged on revenue growth in its latest quarter. \n</p>\n<p>\n  The stock dropped 25% to $11.62 on Thursday. Shares are down 49% this year. \n</p>\n<p>\n  The medical technology company now forecasts adjusted earnings per share of $2.19 to $2.24 for the year, lowering the upper range of its prior projection of $2.19 to $2.29. \n</p>\n<p>\n  Integra also cut its revenue outlook, guiding for sales of $1.62 billion to $1.64 billion, compared to $1.66 billion to $1.68 billion previously. \n</p>\n<p>\n  The updated guidance comes after Integra said third-quarter revenue was negatively affected by two supply interruptions. Chief Executive Mojdeh Poul said the company is working to strengthen its supply chain and quality management system, and is confident it can improve overall performance. \n</p>\n<p>\n  For the third quarter, Integra narrowed its loss to $5.4 million, or 7 cents a share, from a loss of $10.7 million, or 14 cents a share, a year earlier. \n</p>\n<p>\n  Adjusted earnings per share were 54 cents, ahead of estimates of 43 cents a share according to analysts polled by FactSet. \n</p>\n<p>\n  Revenue rose 5.6% to $402.1 million, missing analyst expectations of $414.2 million. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 30, 2025 12:14 ET (16:14 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IART","symbol_name":"英特格拉生命科学","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2579124024","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579124024","pubTimestamp":1761840840,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Integra LifeSciences slid as the company cut its full-year outlook after supply chain interruptions dragged on revenue growth in its latest quarter.The stock dropped 25% to $11.62 on Thursday. Shares are down 49% this year.The medical technology company now forecasts adjusted earnings per share of $2.19 to $2.24 for the year, lowering the upper range of its prior projection of $2.19 to $2.29.Integra also cut its revenue outlook, guiding for sales of $1.62 billion to $1.64 billion, compared to $1.66 billion to $1.68 billion previously.The updated guidance comes after Integra said third-quarter revenue was negatively affected by two supply interruptions. Chief Executive Mojdeh Poul said the company is working to strengthen its supply chain and quality management system, and is confident it can improve overall performance.For the third quarter, Integra narrowed its loss to $5.4 million, or 7 cents a share, from a loss of $10.7 million, or 14 cents a share, a year earlier.Adjuste","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IART":"英特格拉生命科学","BK4082":"医疗保健设备"},"translate_title":"Integra LifeSciences因供应链问题下调财年前景而股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IART":0.9},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  Shares of Integra LifeSciences slid as the company cut its full-year outlook after supply chain interruptions dragged on revenue growth in its latest quarter. \n\n\n  The stock dropped 25% to $11.62 on Thursday. Shares are down 49% this year. \n\n\n  The medical technology company now forecasts adjusted earnings per share of $2.19 to $2.24 for the year, lowering the upper range of its prior projection of $2.19 to $2.29. \n\n\n  Integra also cut its revenue outlook, guiding for sales of $1.62 billion to $1.64 billion, compared to $1.66 billion to $1.68 billion previously. \n\n\n  The updated guidance comes after Integra said third-quarter revenue was negatively affected by two supply interruptions. Chief Executive Mojdeh Poul said the company is working to strengthen its supply chain and quality management system, and is confident it can improve overall performance. \n\n\n  For the third quarter, Integra narrowed its loss to $5.4 million, or 7 cents a share, from a loss of $10.7 million, or 14 cents a share, a year earlier. \n\n\n  Adjusted earnings per share were 54 cents, ahead of estimates of 43 cents a share according to analysts polled by FactSet. \n\n\n  Revenue rose 5.6% to $402.1 million, missing analyst expectations of $414.2 million. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 30, 2025 12:14 ET (16:14 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}